자가면역질환용 IVD 및 LDT 시장 : 제품 유형별, 검사 유형별, 기술별, 검체 유형별, 용도별, 최종 사용자별, 유통 채널별 시장 예측(2026-2032년)

The IVD & LDT For Autoimmune Diseases Market is projected to grow by USD 29.85 billion at a CAGR of 7.15% by 2032.

Autoimmune disease diagnostics sit at the intersection of high clinical need, expanding test menus, and tightening regulatory oversight. More than 80 autoimmune diseases are recognized, including rheumatoid arthritis, systemic lupus erythematosus, celiac disease, autoimmune thyroid disease, inflammatory bowel disease, and type 1 diabetes. Diagnosis often requires a combination of clinical assessment, autoantibody testing, inflammatory markers, histopathology, imaging, and, in selected cases, molecular or genetic assays.

The IVD and LDT ecosystem is central to earlier detection, differential diagnosis, disease stratification, and therapy monitoring. Core autoimmune IVD categories include antinuclear antibody testing, extractable nuclear antigen panels, anti-CCP assays, anti-dsDNA testing, antiphospholipid antibody panels, tissue transglutaminase assays, thyroid autoantibodies, complement testing, and multiplex immunoassays. Laboratory-developed tests continue to support specialized autoimmune diagnostics where rare disease complexity, low-volume indications, or rapidly evolving biomarkers make standardized commercial kits less available.

Demand is reinforced by aging populations, improved disease awareness, wider access to specialist care, and the clinical consequences of delayed diagnosis. In the United States, the National Institutes of Health has cited autoimmune diseases as affecting more than 24 million people, while population studies have documented rising antinuclear antibody prevalence over time. These signals support sustained investment in autoimmune disease testing, quality systems, digital laboratory infrastructure, and evidence-based biomarker validation.

Transformative Shifts in the Autoimmune Diagnostics Landscape

The autoimmune diagnostics landscape is shifting from single-analyte, symptom-triggered testing toward integrated, data-rich diagnostic pathways. Laboratories and manufacturers are expanding from traditional indirect immunofluorescence and ELISA methods into chemiluminescence immunoassays, line immunoassays, multiplex bead-based platforms, microarrays, and automated workflow systems. These technologies improve throughput, reproducibility, and panel-based interpretation, especially in high-volume areas such as ANA reflex testing, rheumatoid arthritis serology, celiac disease screening, and autoimmune thyroid testing.

Regulatory transformation is one of the defining shifts. In the United States, the FDA issued its 2024 final rule to phase out the general enforcement discretion approach for many laboratory-developed tests, increasing the importance of analytical validity, clinical validity, quality management, and post-market oversight. In Europe, the In Vitro Diagnostic Regulation has raised evidence and conformity assessment expectations, particularly for higher-risk diagnostics and companion diagnostics. These reforms are pushing laboratories, IVD manufacturers, and health systems to strengthen documentation, validation, traceability, and clinical performance evidence.

Commercial models are also changing. Reference laboratories, hospital networks, and diagnostic manufacturers are moving toward integrated test utilization management, reflex algorithms, clinical decision support, and digital reporting. The result is a market where differentiation depends not only on assay sensitivity and specificity but also on turnaround time, interpretive clarity, reimbursement alignment, automation compatibility, and proven clinical utility.

Cumulative Impact of Artificial Intelligence on IVD and LDT Workflows

Artificial intelligence is increasingly influencing autoimmune IVD and LDT workflows, although adoption is uneven and strongest where structured datasets, image analysis, and rule-based interpretation already exist. AI-enabled pattern recognition can support ANA immunofluorescence interpretation, reduce inter-reader variability, and improve workflow efficiency in laboratories managing high test volumes. Machine learning models are also being evaluated for combining autoantibody profiles, inflammatory markers, demographics, symptoms, and longitudinal laboratory values to support differential diagnosis and risk stratification.

The cumulative impact of AI is most practical when it enhances, rather than replaces, validated diagnostic processes. In autoimmune testing, false positives and nonspecific autoantibody findings are common clinical challenges; AI can help by incorporating pretest probability, reflex testing rules, and evidence-based reporting logic. This can reduce unnecessary downstream testing and improve the consistency of recommendations across decentralized health systems.

AI adoption must remain anchored in regulatory-grade validation, bias assessment, cybersecurity, and clinical governance. The FDA maintains a public list of AI- and machine learning-enabled medical devices, demonstrating regulatory attention to software-driven diagnostics, while global authorities continue to refine expectations for transparency and lifecycle management. For autoimmune diagnostics, the near-term opportunity is operationally focused: faster image review, smarter reflex pathways, quality control monitoring, and improved physician-facing interpretation.

Key Regional Insights Across North America, Europe, Asia-Pacific, and Emerging Markets

North America remains a leading region for autoimmune IVD and LDT adoption due to high healthcare spending, broad access to specialty laboratories, established reimbursement structures, and a large base of CLIA-certified laboratories. The United States drives innovation in LDT development, reference laboratory scale, and digital test ordering, while Canada supports adoption through publicly funded healthcare systems and provincial laboratory networks. The region is also experiencing a major compliance shift as FDA oversight of many LDTs becomes more formalized.

Europe is shaped by strong clinical guidelines, advanced hospital laboratory infrastructure, and the implementation of the EU IVDR. Germany, France, Italy, Spain, and the Nordic countries are important markets for automated immunoassay systems, autoimmune panels, and standardized laboratory quality frameworks. The United Kingdom, while outside the European Union, continues to be influential through NHS procurement, health technology assessment, and centralized diagnostic initiatives.

Asia-Pacific is one of the fastest-evolving regions for autoimmune disease diagnostics, supported by large patient populations, expanding private healthcare, increasing specialist access, and investment in laboratory automation. China, Japan, India, South Korea, and Australia represent distinct growth pathways, ranging from high-volume hospital testing and domestic IVD manufacturing to advanced reference laboratory networks. Latin America, led by Brazil and Mexico, is expanding access to autoimmune testing through private laboratories and tertiary care centers, although reimbursement variability and uneven specialist distribution remain constraints. The Middle East is investing in advanced diagnostic infrastructure through GCC healthcare modernization programs, particularly in hospital automation and reference laboratory development. Africa remains earlier in adoption, with opportunities centered on laboratory capacity building, affordable assays, workforce training, and regional reference testing models that improve access beyond major urban centers.

Key Group Insights for G7, EU, BRICS, ASEAN, GCC, and NATO Markets

The G7 economies play a central role in autoimmune IVD innovation because they combine advanced healthcare infrastructure, strong regulatory systems, high diagnostic utilization, and mature reimbursement assessment. The United States, Japan, Germany, France, Italy, Canada, and the United Kingdom are influential in assay validation, clinical guideline development, automation adoption, and evidence generation. Their laboratories are also among the earliest adopters of digital pathology, AI-assisted interpretation, laboratory information system connectivity, and integrated clinical decision support.

The European Union is a pivotal group because the IVDR has changed market access requirements for IVD manufacturers and clinical laboratories serving EU member states. Stronger clinical evidence, post-market surveillance, and notified body involvement are reshaping product portfolios and encouraging a focus on well-validated autoimmune assays. NATO countries overlap significantly with North American and European markets, creating common demand for resilient supply chains, cybersecurity, standardized laboratory readiness, and continuity of diagnostic services across civilian and defense-linked health systems.

BRICS countries represent scale and long-term demand expansion, particularly through China, India, and Brazil, while Russia and South Africa add regional diagnostic capacity and localized healthcare priorities. These markets are expanding laboratory networks, domestic IVD production, and access to specialist diagnostics, although affordability and regional disparities remain important. ASEAN is gaining relevance as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines invest in private healthcare, medical tourism, public laboratory modernization, and specialty care access. The GCC is advancing through high-spending healthcare systems in Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman, where premium diagnostics, hospital automation, reference laboratory partnerships, and national health transformation programs are increasingly important.

Key Country Insights for Major Autoimmune IVD and LDT Markets

The United States is the most influential country market for autoimmune LDTs because of its large reference laboratory sector, CLIA framework, specialist physician base, and rapid adoption of advanced assays. FDA's 2024 LDT final rule is reshaping compliance strategies, validation investments, and partnerships between laboratories and IVD manufacturers. Canada shows steady demand through provincial health systems and accredited laboratory networks, while Mexico is expanding autoimmune testing through private laboratories and urban hospital networks. Brazil leads Latin America with a large population, established private diagnostics infrastructure, tertiary care capacity, and growing access to immunology testing.

In Europe, Germany benefits from advanced laboratory automation, strong hospital infrastructure, and a major diagnostics manufacturing base. France, Italy, and Spain show sustained demand for autoimmune serology across rheumatology, gastroenterology, endocrinology, dermatology, neurology, and nephrology pathways. The United Kingdom remains important through NHS laboratory networks, health technology assessment, and centralized procurement models. Russia has domestic diagnostic capacity and demand for autoimmune testing, but international supply dynamics, localization requirements, and regulatory complexity can influence access to advanced platforms.

In Asia-Pacific, China combines large testing volumes, expanding hospital infrastructure, domestic IVD manufacturing scale, and policy support for local medical technology capability. India is growing through private diagnostic chains, rising specialist access, expanding urban healthcare networks, and increasing autoimmune disease awareness, although affordability and geographic variation remain challenges. Japan and South Korea are mature, technology-forward markets with high laboratory quality expectations, strong automation adoption, and advanced hospital-based diagnostic pathways. Australia supports advanced autoimmune diagnostics through public-private laboratory networks, specialist care pathways, national quality assurance practices, and broad use of standardized laboratory accreditation systems.

Actionable Recommendations for Autoimmune Diagnostics Industry Leaders

Industry leaders should prioritize evidence generation, regulatory readiness, and clinically meaningful differentiation. Autoimmune assays must demonstrate analytical performance, clinical validity, reproducibility, and clear interpretive value across diverse patient populations. Organizations should prepare for more demanding regulatory expectations by strengthening design controls, validation documentation, quality management systems, post-market surveillance, and real-world performance monitoring.

Commercial success will depend on workflow integration. Manufacturers and laboratories should develop autoimmune testing solutions that support reflex algorithms, automated sample handling, laboratory information system connectivity, digital result interpretation, and clinician-friendly reporting. In high-volume segments, automation and turnaround time can be decisive; in rare or complex autoimmune diseases, scientific credibility and specialist interpretation are more important.

Research Methodology for Evidence-Based Autoimmune IVD and LDT Analysis

This executive summary is built on a structured secondary research methodology aligned with healthcare market intelligence standards. The analysis synthesizes information from regulatory agencies, public health institutions, peer-reviewed literature, clinical laboratory standards, public disclosures, and recognized healthcare organizations. Key reference areas include FDA IVD and LDT policy, EU IVDR implementation, CLIA laboratory oversight, NIH autoimmune disease information, population-based autoantibody studies, clinical practice guidelines, and published evidence on autoimmune biomarker testing.

The research approach emphasizes triangulation across regulatory, clinical, technological, and commercial signals. Market direction is assessed by reviewing diagnostic platform evolution, laboratory automation trends, test utilization patterns, reimbursement considerations, and regional healthcare infrastructure. Country and regional insights are interpreted through healthcare access, laboratory capacity, regulatory maturity, disease awareness, specialist availability, and adoption of advanced immunoassay and molecular diagnostic technologies.

No unsupported market sizing claims are used in this summary. All conclusions are framed around verifiable industry drivers, documented regulatory changes, recognized clinical needs, and observable technology trends affecting autoimmune IVDs and laboratory-developed tests.

Conclusion: Evidence, Automation, and Compliance Define Future Growth

The IVD and LDT market for autoimmune diseases is entering a more evidence-driven, technology-enabled, and regulated phase. Rising clinical demand, improved awareness, and the complexity of autoimmune diagnosis are supporting continued need for accurate autoantibody testing, multiplex panels, automated immunoassays, and specialized laboratory-developed tests.

The strongest opportunities will favor organizations that combine scientific validity with operational excellence. Regulatory changes in the United States and Europe are raising expectations, while Asia-Pacific, Latin America, the Middle East, and Africa are expanding diagnostic access at different speeds. AI will add value where it improves reproducibility, workflow efficiency, and clinical interpretation within validated laboratory systems.

For industry leaders, the strategic priority is clear: build trustworthy autoimmune diagnostics that are clinically useful, scalable, compliant, and integrated into real-world care pathways. Organizations that align innovation with evidence, quality, and physician decision-making will be best positioned to compete in the evolving autoimmune disease diagnostics market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. IVD & LDT For Autoimmune Diseases Market, by Product Type

• 7.1. In Vitro Diagnostic
• 7.2. Lab Developed Test

8. IVD & LDT For Autoimmune Diseases Market, by Test Type

• 8.1. Antinuclear Antibody (ANA) Tests
  • 8.1.1. ELISA-based ANA
  • 8.1.2. IFA-based ANA
• 8.2. Autoantibody Tests
  • 8.2.1. Anti-dsDNA
  • 8.2.2. Anti-CCP
  • 8.2.3. Anti-ENA Panel
• 8.3. Inflammatory Marker Tests
  • 8.3.1. CRP
  • 8.3.2. ESR
• 8.4. Genetic Tests
  • 8.4.1. HLA Typing
  • 8.4.2. SNP-based Testing

9. IVD & LDT For Autoimmune Diseases Market, by Technology

• 9.1. Immunoassay
  • 9.1.1. ELISA
  • 9.1.2. CLIA
  • 9.1.3. RIA
  • 9.1.4. FIA
• 9.2. Molecular Diagnostics
  • 9.2.1. PCR
  • 9.2.2. NGS
  • 9.2.3. Microarrays
• 9.3. Flow Cytometry
• 9.4. Immunofluorescence

10. IVD & LDT For Autoimmune Diseases Market, by Sample Type

• 10.1. Tissue Biopsies
• 10.2. Saliva
• 10.3. Urine
• 10.4. Blood
  • 10.4.1. Serum
  • 10.4.2. Plasma

11. IVD & LDT For Autoimmune Diseases Market, by Application

• 11.1. Celiac Disease
• 11.2. Multiple Sclerosis
• 11.3. Rheumatoid Arthritis
• 11.4. Systemic Lupus Erythematosus
• 11.5. Type 1 Diabetes

12. IVD & LDT For Autoimmune Diseases Market, by End User

• 12.1. Academic & Research Institutes
• 12.2. Diagnostic Laboratories
• 12.3. Hospital
  • 12.3.1. Public
  • 12.3.2. Private
• 12.4. Reference Laboratories

13. IVD & LDT For Autoimmune Diseases Market, by Distribution Channel

• 13.1. Offline
• 13.2. Online

14. IVD & LDT For Autoimmune Diseases Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. IVD & LDT For Autoimmune Diseases Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. IVD & LDT For Autoimmune Diseases Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. A. Menarini Diagnostics s.r.l.
• 18.2. Abbott Laboratories
• 18.3. Adaptive Biotechnologies Corporation
• 18.4. AESKU.GROUP GmbH & Co. KG
• 18.5. Agilent Technologies, Inc.
• 18.6. Bio-Rad Laboratories, Inc.
• 18.7. bioMerieux S.A.
• 18.8. Corgenix, Inc.
• 18.9. Danaher Corporation
• 18.10. DiaSorin S.p.A.
• 18.11. EUROIMMUN Medizinische Labordiagnostika AG
• 18.12. Exagen Inc.
• 18.13. F. Hoffmann-La Roche Ltd
• 18.14. Gold Standard Diagnostics
• 18.15. Grifols, S.A.
• 18.16. Hycor Biomedical LLC
• 18.17. Inova Diagnostics, Inc.
• 18.18. KRONUS
• 18.19. LabCorp
• 18.20. Myriad Genetics, Inc.
• 18.21. Omega Diagnostics Group plc
• 18.22. Quest Diagnostics Incorporated
• 18.23. QuidelOrtho Corporation
• 18.24. Revvity, Inc.
• 18.25. Sebia
• 18.26. Seramun Diagnostica GmbH
• 18.27. Siemens Healthineers AG
• 18.28. Thermo Fisher Scientific Inc.
• 18.29. Werfen S.A.